Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | August 14, 2024 | August 16, 2024 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Director | October 26, 2016 | October 27, 2016 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director | June 26, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date August 14, 2024 · Filed August 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 46,069 |
Ending reported balance
After 2024-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-14 · Exercise / conversion · Acquired 54,915 · Balance 54,915 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. Row 2 · 2024-08-14 · Sale · Disposed 8,846 · Balance 46,069 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2024-11-13 | Direct | 0 |
Reported balance
After 2024-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-14 · Exercise / conversion · Disposed 54,915 · Balance 0 F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. F2: This is a director stock option grant that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold.
F2: This is a director stock option grant that is fully vested.
Myovant Sciences Ltd.
Report date October 26, 2016 · Filed October 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
Holding disclosure · report date 2016-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 F1: Does not include 37,231,342 shares owned by Roivant Sciences Ltd. ("Roivant"). Dr. Manchester is one of five directors of Roivant. Dr. Manchester expressly disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not include 37,231,342 shares owned by Roivant Sciences Ltd. ("Roivant"). Dr. Manchester is one of five directors of Roivant. Dr. Manchester expressly disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his pecuniary interest therein.
Roivant Sciences Ltd.
Report date June 26, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectHeld by QVT Financial Investment Cayman Ltd. | 13,689,166 |
Last balance in matching sequence
After 2026-06-30 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-06-26 · Sale · Disposed 300,783 · Balance 14,826,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 2 · 2026-06-26 · Sale · Disposed 325,000 · Balance 14,501,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 3 · 2026-06-29 · Sale · Disposed 200,000 · Balance 14,301,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 4 · 2026-06-29 · Sale · Disposed 600,000 · Balance 13,701,546 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Row 5 · 2026-06-30 · Sale · Disposed 12,380 · Balance 13,689,166 F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | Direct | 1,748,403 |
Reported balance
After 2026-06-30 transaction · row 6
1 source rowRow 6 · 2026-06-30 · Sale · Disposed 200,000 · Balance 1,748,403 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $35.45 | $7,090,000.00 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 6 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,748,403 Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 12,380 | $35.28 | $436,766.40 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 5 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 13,689,166 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 600,000 | $34.59 | $20,754,000.00 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 13,701,546 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $34.44 | $6,888,000.00 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 14,301,546 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 26, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 325,000 | $34.07 | $11,072,750.00 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 14,501,546 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 26, 2026 Filed Jul 1, 2026 00:38 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 300,783 | $33.92 | $10,202,559.36 |
DisclosureSEC source: 0001193125-26-291172 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 14,826,546 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2026 Filed Feb 14, 2026 02:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 225,000 | $26.50 | $5,962,500.00 |
DisclosureSEC source: 0001193125-26-052130 · ownership.xml · nonDerivative · entry 5 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 15,127,329 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2026 Filed Feb 14, 2026 02:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 150,784 | $26.49 | $3,994,268.16 |
DisclosureSEC source: 0001193125-26-052130 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 15,352,329 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 02:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 275,000 | $26.76 | $7,359,000.00 |
DisclosureSEC source: 0001193125-26-052130 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 15,503,113 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 02:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 150,000 | $26.72 | $4,008,000.00 |
DisclosureSEC source: 0001193125-26-052130 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 15,778,113 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 02:02 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 425,000 | $26.67 | $11,334,750.00 |
DisclosureSEC source: 0001193125-26-052130 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 15,928,113 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 00:52 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 189,538 | $23.17 | $4,391,595.46 |
DisclosureSEC source: 0001193125-25-325355 · ownership.xml · nonDerivative · entry 5 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 16,353,113 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 00:52 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 155,076 | $23.02 | $3,569,849.52 |
DisclosureSEC source: 0001193125-25-325355 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 16,542,651 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 00:52 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 432,718 | $23.05 | $9,974,149.90 |
DisclosureSEC source: 0001193125-25-325355 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 16,697,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 00:52 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 642,282 | $23.08 | $14,823,868.56 |
DisclosureSEC source: 0001193125-25-325355 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 17,130,445 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 00:52 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 275,000 | $22.93 | $6,305,750.00 |
DisclosureSEC source: 0001193125-25-325355 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 17,772,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:24 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 175,000 | $20.24 | $3,542,000.00 |
DisclosureSEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 18,047,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:24 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 125,000 | $20.16 | $2,520,000.00 |
DisclosureSEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 18,222,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:24 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 150,000 | $20.20 | $3,030,000.00 |
DisclosureSEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 18,347,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 01:24 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 850,000 | $20.25 | $17,212,500.00 |
DisclosureSEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 18,497,727 F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 33,726 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0001140361-25-034934 · form4.xml · derivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,726 Underlying: Common Shares · 33,726 shares Expires 2035-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 14,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034934 · form4.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,948,403 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 21:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,170,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090994 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT P&E Roiv Hldgs Ltd. Disclosed balance after: 1,592,480 F1 · kind: On June 25, 2025, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. One of the investors in QVT Roiv Hldgs Offshore Ltd., a related fund, contributed its pro rata portion distribution to QVT FIC in order to facilitate the winding down of QVT Roiv Hldgs Offshore Ltd. QVT FIC has no pecuniary interest in such shares. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 21:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 6,837,266 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090994 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Roiv Hldgs Onshore Ltd. Disclosed balance after: 0 F1 · kind: On June 25, 2025, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. One of the investors in QVT Roiv Hldgs Offshore Ltd., a related fund, contributed its pro rata portion distribution to QVT FIC in order to facilitate the winding down of QVT Roiv Hldgs Offshore Ltd. QVT FIC has no pecuniary interest in such shares. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 21:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 3,176,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090994 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 19,347,727 F1 · kind: On June 25, 2025, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. One of the investors in QVT Roiv Hldgs Offshore Ltd., a related fund, contributed its pro rata portion distribution to QVT FIC in order to facilitate the winding down of QVT Roiv Hldgs Offshore Ltd. QVT FIC has no pecuniary interest in such shares. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 21:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 6,205,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-090994 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Deferred Compensation Holdings Ltd Disclosed balance after: 8,441,428 F1 · kind: On June 25, 2025, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. One of the investors in QVT Roiv Hldgs Offshore Ltd., a related fund, contributed its pro rata portion distribution to QVT FIC in order to facilitate the winding down of QVT Roiv Hldgs Offshore Ltd. QVT FIC has no pecuniary interest in such shares. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 00:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 134,948 | $11.77 | $1,587,703.70 |
DisclosureSEC source: 0000950170-24-109733 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,277,178 Read SEC document |
| September 24, 2024 Filed Sep 27, 2024 00:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 368,052 | $11.63 | $4,278,604.50 |
DisclosureSEC source: 0000950170-24-109733 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,412,126 Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 27,894 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001140361-24-040988 · form4.xml · derivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,894 Underlying: Common Shares · 27,894 shares Expires 2034-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-040988 · form4.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,780,178 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:07 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionStock Option (Right to Buy) · Derivative | 54,915 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001447028-24-000078 · wk-form4_1723838854.xml · derivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 54,915 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. F2 · derivative.exercise_date: This is a director stock option grant that is fully vested. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:07 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | SaleCommon Shares | 8,846 | $3.69 | $32,637.32 |
DisclosureSEC source: 0001447028-24-000078 · wk-form4_1723838854.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,069 F1 · kind: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:07 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | Exercise / conversionCommon Shares | 54,915 | $0.56 | $30,752.40 |
DisclosureSEC source: 0001447028-24-000078 · wk-form4_1723838854.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:16 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001447028-24-000057 · wk-form4_1716581747.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2034-05-23 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,260,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028216 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT P&E Roiv Hldgs Ltd. Disclosed balance after: 2,763,126 F1 · kind: On March 7, 2024, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 5,594,064 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028216 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Roiv Hldgs Onshore Ltd. Disclosed balance after: 6,837,266 F1 · kind: On March 7, 2024, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 11,325,233 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028216 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 23,105,358 F1 · kind: On March 7, 2024, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:35 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 11,077,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-028216 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Deferred Compensation Holdings Ltd Disclosed balance after: 14,646,796 F1 · kind: On March 7, 2024, each of QVT Roiv Hldgs Onshore Ltd. (together, "QVT Roiv"), QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC") made an in-kind distribution on a pro rata basis, for no consideration. F2 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv, QVT DCH, QVT P&E and QVT FIC (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 01:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 446,394 | $11.55 | $5,155,850.70 |
DisclosureSEC source: 0000950170-23-051250 · ownership.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT P&E Roiv Hldgs Ltd. Disclosed balance after: 5,023,787 F1 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 01:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,104,599 | $11.55 | $12,758,118.45 |
DisclosureSEC source: 0000950170-23-051250 · ownership.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Roiv Hldgs Onshore Ltd Disclosed balance after: 12,431,330 F1 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 01:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 3,059,368 | $11.55 | $35,335,700.40 |
DisclosureSEC source: 0000950170-23-051250 · ownership.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 34,430,591 F1 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 01:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 2,285,783 | $11.55 | $26,400,793.65 |
DisclosureSEC source: 0000950170-23-051250 · ownership.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by QVT Deferred Compensation Holdings Ltd Disclosed balance after: 25,724,561 F1 · ownership.direct: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 26,595 | $0.00 Strike: $11.22 | $0.00 |
DisclosureSEC source: 0001140361-23-044041 · form4.xml · derivative · entry 6 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Shares · 26,595 shares Expires 2033-09-11 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 17,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-044041 · form4.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,967 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:18 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001447028-23-000044 · wk-form4_1685132251.xml · derivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2033-05-24 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 24, 2023, the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 146,079 | $4.75 | $693,875.25 |
DisclosureSEC source: 0000899243-22-035815 · doc4.xml · nonDerivative · entry 5 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by QVT P&E Roiv Hldgs Ltd. Disclosed balance after: 5,470,181 F2 · ownership.nature: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 2,311,643 | $4.75 | $10,980,304.25 |
DisclosureSEC source: 0000899243-22-035815 · doc4.xml · nonDerivative · entry 4 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by QVT Deferred Compensation Holdings Ltd. Disclosed balance after: 28,010,344 F2 · ownership.nature: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 372,427 | $4.75 | $1,769,028.25 |
DisclosureSEC source: 0000899243-22-035815 · doc4.xml · nonDerivative · entry 3 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by QVT Roiv Hldgs Onshore Ltd. Disclosed balance after: 13,535,929 F2 · ownership.nature: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 1,092,355 | $4.75 | $5,188,686.25 |
DisclosureSEC source: 0000899243-22-035815 · doc4.xml · nonDerivative · entry 2 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 37,489,959 F2 · ownership.nature: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 09, 2022 Filed Nov 15, 2022 02:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 1,196,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035815 · doc4.xml · nonDerivative · entry 1 MANCHESTER KEITH S · CIK 0001244828 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd. Disclosed balance after: 38,582,314 F1 · price: Shares were distributed in-kind to certain shareholders of QVT Financial Investment Cayman Ltd. who subsequently gifted the shares to charitable foundations, each of which is subject to a lock-up. F2 · ownership.nature: The reporting person is a shareholder of each of QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&E Roiv Hldgs Ltd. and QVT Financial Investment Cayman Ltd. (the "QVT Entities") but does not have any voting or investment control over the QVT Entities. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.